Researchers are exploring whether the common amino acid arginine could offer a new approach to combatting Alzheimer’s disease, a condition currently affecting over 6 million Americans[[2]]. A new study indicates that oral arginine supplementation in animal models may slow the progression of the disease by reducing amyloid buildup and neuroinflammation[[3]]. While preliminary, these findings-published online October 30, 2025, in *Neurochemistry International*-are prompting further investigation into arginine’s potential as a safe and inexpensive therapeutic option[[1]].
Oral Arginine Supplementation May Slow Alzheimer’s Progression in Animal Models
Supplementation with the amino acid arginine may offer a potential therapeutic avenue for Alzheimer’s disease, according to research conducted on animal models. The study, which explored the impact of oral arginine administration, suggests a possible slowing of disease development.
Researchers investigated the effects of arginine in preclinical models of Alzheimer’s. Their findings indicate that the supplement could influence the progression of the disease, offering a glimmer of hope for future treatment strategies. Alzheimer’s disease is a growing public health concern, impacting millions worldwide, and new avenues for intervention are critically needed.
The research team’s work focused on understanding how arginine impacts key pathological processes associated with Alzheimer’s. While the study was performed on animal models, the results suggest that arginine warrants further investigation as a potential therapeutic option.
Further research is needed to determine if these findings translate to humans and to establish optimal dosage and long-term effects. The study’s results provide a foundation for future clinical trials exploring arginine’s potential role in managing Alzheimer’s disease.
